Besides, prescriptions filled at comparable stores augmented 3.0% from the year-ago quarter. Prescription sales constituted about 66.5% of total drugstore sales, while third party prescription revenues represented 96.6% of the pharmacy sales. Rite Aid's gross profit elevated 14.9% year over year to $2,047.8 million, with gross margin expanding 680 basis points to 31.7%, primarily driven by new generic drugs introductions. Selling General and Administrative expenses decreased 4.3% to $1,682.3 million, while as a percentage of sales it expanded 150 bps to 26.1%. Rite Aid reported adjusted EBITDA of $340.3 million, up 24.0% from $274.3 million in the prior-year quarter. As a percentage of sales, it improved 150 bps to 5.3%, gaining from higher pharmacy gross margin driven by new generic introductions and strong prescription count growth, partially offset by one lesser comparable week.